Another Phase 1/2 Trial With SX-682, Combined With Docetaxel This Time

SX-682 is moving into a new clinical context. After an ongoing trial in prostate cancer with androgen receptor pathway inhibitors such as apalutamide and enzalutamide, the CXCR1/2 inhibitor is now being studied with docetaxel in recurrent/metastatic head and neck squamous cell carcinoma, salivary gland carcinoma, and advanced prostate cancer. That matters because docetaxel is not just another partner drug: it brings SX-682 into a taxane-based setting where the rationale is to attack both the tumor cell and the inflammatory microenvironment that helps the cancer resist treatment.

The biologic logic for this move is strong. SX-682 blocks CXCR1 and CXCR2, two chemokine receptors involved in recruiting myeloid-derived suppressor cells and other suppressive immune populations into tumors, which can blunt antitumor immunity and contribute to treatment resistance. In preclinical head and neck cancer models, SX-682 plus docetaxel produced stronger tumor control than either agent alone, with evidence of enhanced taxane sensitivity and a more favorable immune milieu. That preclinical package makes the docetaxel combination feel like a logical extension of the SX-682 story.

For prostate cancer, the new trial is notable because it broadens SX-682 beyond the ARPI-resistance angle that has dominated recent discussion. The combination of SX-682 with enzalutamide or apalutamide already in the field, and a separate biomarker study is examining CXCR2-related predictors of benefit in that program. But docetaxel brings SX-682 into a standard chemotherapy backbone that remains central in advanced prostate cancer, especially mCRPC, where resistance and immune escape remain major problems.

Clinical trial.